Bizengri Injection
NDC Package 71837-1000-2
Package Information
Bizengri (zenocutuzumab) injection is none. This formulation utilizes a injection delivery system. Marketed by Partner Therapeutics, Inc., this product is identified by NDC 71837-1000 and is authorized under FDA application BLA761352.
Identification & Billing
- RxCUI: 2699594 - zenocutuzumab-zbco 375 MG in 18.75 ML Injection
- RxCUI: 2699594 - 18.75 ML zenocutuzumab-zbco 20 MG/ML Injection
- RxCUI: 2699594 - zenocutuzumab-zbco 375 MG per 18.75 ML Injection
- RxCUI: 2699601 - Bizengri 375 MG in 18.75 ML Injection
- RxCUI: 2699601 - 18.75 ML zenocutuzumab-zbco 20 MG/ML Injection [Bizengri]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 71837 - Partner Therapeutics, Inc.
- 71837-1000 - Bizengri
- 71837-1000-2 - 2 VIAL, GLASS in 1 CARTON / 18.75 mL in 1 VIAL, GLASS (71837-1000-1)
- 71837-1000 - Bizengri
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71837-1000-2 identifies a specific commercial package of 2 vial, glass in 1 carton / 18.75 ml in 1 vial, glass (71837-1000-1) of Bizengri, a human prescription drug labeled by Partner Therapeutics, Inc.. This injection is formulated for intravenous use and contains zenocutuzumab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Partner Therapeutics, Inc. on December 04, 2024. The current certification is valid through December 31, 2027.
How is this Partner Therapeutics, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71837100002. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.